Published in J Exp Med on December 17, 2001
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med (2015) 2.42
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood (2007) 2.28
For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer (2010) 2.26
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest (2009) 2.11
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem (2002) 1.94
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature (2008) 1.91
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2013) 1.91
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.90
Malignant pirates of the immune system. Nat Immunol (2011) 1.87
Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell (2010) 1.85
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia (2006) 1.81
Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med (2009) 1.80
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer (2010) 1.80
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood (2010) 1.77
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer (2014) 1.76
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med (2008) 1.74
Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol (2012) 1.72
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res (2011) 1.67
Roles of the NF-kappaB pathway in lymphocyte development and function. Cold Spring Harb Perspect Biol (2009) 1.63
Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest (2003) 1.63
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res (2010) 1.58
Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One (2009) 1.52
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood (2015) 1.51
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood (2010) 1.48
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood (2016) 1.45
Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med (2008) 1.42
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A (2008) 1.42
How I treat HIV-associated lymphoma. Blood (2012) 1.42
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2010) 1.40
The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci U S A (2006) 1.39
Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell (2014) 1.39
MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci (2010) 1.37
A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn (2010) 1.37
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation. EMBO J (2011) 1.34
NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer (2010) 1.33
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer (2008) 1.32
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell (2013) 1.30
Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics (2012) 1.29
The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association. Mol Cell Biol (2008) 1.26
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A (2014) 1.25
Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol (2007) 1.24
Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet (2006) 1.24
NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood (2005) 1.22
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol Cell Biol (2007) 1.20
NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem (2010) 1.20
Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med (2012) 1.19
Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med (2014) 1.18
Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells. PLoS One (2012) 1.16
A critical role for the NFkB pathway in multiple myeloma. Oncotarget (2010) 1.15
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget (2015) 1.15
Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm (2009) 1.14
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res (2014) 1.13
Manganese porphyrin, MnTE-2-PyP5+, Acts as a pro-oxidant to potentiate glucocorticoid-induced apoptosis in lymphoma cells. Free Radic Biol Med (2012) 1.12
The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol (2013) 1.12
Regulation of NF-κB by the CARD proteins. Immunol Rev (2012) 1.12
Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol (2011) 1.11
A perspective on DNA microarrays in pathology research and practice. Am J Pathol (2007) 1.11
Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res (2007) 1.09
Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. Am J Pathol (2003) 1.08
B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol (2015) 1.08
Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res (2009) 1.08
Structural studies of NF-κB signaling. Cell Res (2010) 1.07
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood (2007) 1.06
A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival. Mol Cell Biol (2012) 1.06
Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol (2010) 1.04
S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood (2012) 1.02
Gadd45 proteins as critical signal transducers linking NF-kappaB to MAPK cascades. Curr Cancer Drug Targets (2009) 1.00
NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res (2011) 1.00
Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood (2012) 0.98
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 20.70
Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 16.95
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol (1994) 8.98
Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science (1995) 8.75
The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell (1997) 8.74
NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature (1999) 8.42
In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell (1997) 7.18
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science (1999) 5.95
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 5.87
Aberrant rel/nfkb genes and activity in human cancer. Oncogene (1999) 5.62
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev (1995) 5.51
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 5.36
NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 4.55
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science (1997) 4.23
The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev (1993) 4.23
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell (1991) 3.84
A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol (1992) 3.63
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 3.34
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett (1998) 3.32
NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol (1999) 3.30
The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev (1999) 3.25
Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A (1994) 3.24
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest (1997) 3.22
A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood (2000) 3.13
NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A (1999) 2.83
Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev (1999) 2.82
Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol (2000) 2.67
NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med (1997) 2.66
Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem (1997) 2.55
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med (2000) 2.25
B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med (1998) 2.00
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev (1998) 1.99
E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination. EMBO J (1999) 1.93
Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med (2000) 1.92
Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem (1996) 1.91
Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc Natl Acad Sci U S A (1994) 1.89
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood (1996) 1.85
Constitutive activation of NF-kappa B is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein. EMBO J (1996) 1.85
High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood (1996) 1.82
Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem (2001) 1.80
The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J (2000) 1.79
Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene (1999) 1.71
Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med (2000) 1.60
Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem (2000) 1.59
Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene (1993) 1.51
Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev (2000) 1.51
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene (1999) 1.41
Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem (2000) 1.39
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood (1996) 1.35
Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative. J Biol Chem (1997) 1.32
Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene (1997) 1.31
Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol (2000) 1.21
Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol (1995) 1.21
The molecular and cellular origins of Hodgkin's disease. J Exp Med (2000) 1.21
Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene (2001) 1.12
Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene (2000) 1.10
The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. J Virol (2000) 1.08
The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes. J Biol Chem (2001) 1.07
Alterations at the rel locus in human lymphoma. Oncogene (1991) 1.05
Naturally occurring and synthetic inhibitors of NF-kappaB functions. Anticancer Drug Des (2000) 1.00
Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene (2000) 0.91
Molecular analysis of cutaneous B- and T-cell lymphomas. Blood (1995) 0.89
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
E. coli RNA polymerase interacts homologously with two different promoters. Cell (1980) 19.71
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Contacts between Escherichia coli RNA polymerase and an early promoter of phage T7. Proc Natl Acad Sci U S A (1980) 9.32
Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell (1981) 9.09
Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science (1995) 8.75
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature (1986) 8.64
Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science (1997) 6.58
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell (1984) 5.61
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 5.36
Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci U S A (1993) 4.99
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature (1990) 4.69
RNA polymerase unwinds an 11-base pair segment of a phage T7 promoter. Nature (1979) 4.63
Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature (1990) 4.61
T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature (1993) 4.57
Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol (2001) 4.09
RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol (1992) 4.03
RNA polymerase interaction at the promoter--operator region of the tryptophan operon of Escherichia coli and Salmonella typhimurium. J Mol Biol (1978) 3.84
Signatures of the immune response. Immunity (2001) 3.66
A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol (1992) 3.63
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell (1993) 3.35
Formation of aromatic amino acid pools in Escherichia coli K-12. J Bacteriol (1970) 3.32
Nucleotide sequence of region preceding trp mRNA initiation site and its role in promoter and operator function. Proc Natl Acad Sci U S A (1976) 3.13
Inositol trisphosphate formation and calcium mobilization in Swiss 3T3 cells in response to platelet-derived growth factor. Biochem J (1984) 3.07
Human immunoglobulin D segments encoded in tandem multigenic families. Nature (1981) 2.99
The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature (1992) 2.95
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest (1983) 2.91
Regulation of aromatic amino acid biosynthesis Escherichia coli K12. Genetics (1968) 2.83
Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med (1998) 2.80
PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science (1993) 2.80
Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol Cell Biol (1986) 2.76
Structure and regulation of aroH, the structural gene for the tryptophan-repressible 3-deoxy-D-arabino-heptulosonic acid-7-phosphate synthetase of Escherichia coli. J Mol Biol (1981) 2.62
Control of aromatic biosynthesis: the multiplicity of 7-phospho-2-oxo-3-deoxy-D-arabino-heptonate D-erythrose-4-phosphate-lyase (pyruvate-phosphorylating) in Escherichia coli W. Biochim Biophys Acta (1965) 2.53
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Complexity of the primary genetic response to mitogenic activation of human T cells. Mol Cell Biol (1989) 2.40
A human protein specific for the immunoglobulin octamer DNA motif contains a functional homeobox domain. Cell (1988) 2.32
Nucleotide sequence of the three major early promoters of bacteriophage T7. Nucleic Acids Res (1979) 2.32
Inhibition of epidermal growth factor binding to surface receptors by tumor promotors. Biochem Biophys Res Commun (1979) 2.32
Repression of aromatic amino acid biosynthesis in Escherichia coli K-12. J Bacteriol (1971) 2.29
Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol (2000) 2.28
Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med (1983) 2.27
The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut (2008) 2.26
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A (2000) 2.24
Specificity of inositol trisphosphate-induced calcium release from permeabilized Swiss-mouse 3T3 cells. Biochem J (1984) 2.18
Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development (2000) 2.10
Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol (1978) 2.06
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science (1989) 2.01
High-affinity binding site for a specific nuclear protein in the human IgM gene. Nature (1985) 2.00
BCL-6 expression during B-cell activation. Blood (1996) 1.95
Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc Natl Acad Sci U S A (1995) 1.95
Gem: an induced, immediate early protein belonging to the Ras family. Science (1994) 1.94
Transcriptional repression by the proto-oncogene BCL-6. Oncogene (1996) 1.94
Maintenance and exchange of the aromatic amino acid pool in Escherichia coli. J Bacteriol (1971) 1.93
The regulation and expression of c-myc in normal and malignant cells. Annu Rev Immunol (1986) 1.90
Reduction of epidermal growth factor receptor affinity by heterologous ligands: evidence for a mechanism involving the breakdown of phosphoinositides and the activation of protein kinase C. Biochem Biophys Res Commun (1984) 1.83
Density-dependent regulation of growth of BSC-1 cells in cell culture: control of growth by serum factors. Proc Natl Acad Sci U S A (1977) 1.81
Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J Biol Chem (1996) 1.78
Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet (1997) 1.76
Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells. J Cell Physiol (1985) 1.72
Nucleotide sequence of the promoter--operator region of the tryptophan operon of Escherichia coli. J Mol Biol (1978) 1.69
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J (1993) 1.61
T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci U S A (1998) 1.58
Programmes, resources, and needs of HIV-prevention nongovernmental organizations (NGOs) in Africa, Central/Eastern Europe and Central Asia, Latin America and the Caribbean. AIDS Care (2006) 1.58
The nucleotide sequence of a cDNA encoding an EGF-inducible gene indicates the existence of a new family of mitogen-induced genes. Oncogene (1990) 1.57
Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity (1997) 1.56
Effects of bombesin and insulin on inositol (1,4,5)trisphosphate and inositol (1,3,4)trisphosphate formation in Swiss 3T3 cells. Cell (1986) 1.55
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A (1998) 1.54
A comparison of the binding of epidermal growth factor to cultured granulosa and luteal cells. J Biol Chem (1978) 1.53
V region gene usage and somatic mutation in the primary and secondary responses to influenza virus hemagglutinin. J Immunol (1990) 1.49
Control of three isoenzymic 7-phospho-2-oxo-3-deoxy-Darabino-heptonate-D-erythrose-4-phosphate lyases of Escherichia coli W and derived mutants by repressive and "inductive" effects of the aromatic amino acids. Biochim Biophys Acta (1966) 1.47
CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc Natl Acad Sci U S A (2000) 1.47
Probing lymphocyte biology by genomic-scale gene expression analysis. J Clin Immunol (1998) 1.46
ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc Natl Acad Sci U S A (2000) 1.46
Localization of human variable and constant region immunoglobulin heavy chain genes on subtelomeric band q32 of chromosome 14. Nucleic Acids Res (1982) 1.45
Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci U S A (1993) 1.44
Kinetic analysis of human T-cell leukemia virus type I Tax-mediated activation of NF-kappa B. Mol Cell Biol (1994) 1.43
The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia (2011) 1.43
CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol (1996) 1.42
Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin. EMBO J (1986) 1.40
Characterization of an epithelioid cell line derived from rat small intestine: demonstration of cytokeratin filaments. Cell Biol Int Rep (1984) 1.38
Early phosphorylation events following the treatment of Swiss 3T3 cells with bombesin and the mammalian bombesin-related peptide, gastrin-releasing peptide. EMBO J (1986) 1.38
Mitogenic activation of human T cells induces two closely related genes which share structural similarities with a new family of secreted factors. J Immunol (1989) 1.37
Vasopressin inhibition of epidermal growth factor binding to cultured mouse cells. J Biol Chem (1981) 1.36
Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev (2001) 1.35
Borrelia burgdorferi activates nuclear factor-kappa B and is a potent inducer of chemokine and adhesion molecule gene expression in endothelial cells and fibroblasts. J Immunol (1997) 1.35
Nucleotide sequence of the promoter--operator region of the tryptophan operon of Salmonella typhimurium. J Mol Biol (1978) 1.33
Inhibition of epidermal growth factor binding to mouse cultured cells by fibroblast-derived growth factor. Evidence for an indirect mechanism. J Biol Chem (1982) 1.33
Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative. J Biol Chem (1997) 1.32
Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family. EMBO J (2001) 1.31
Physical and functional interaction of filamin (actin-binding protein-280) and tumor necrosis factor receptor-associated factor 2. J Biol Chem (2000) 1.31
Two inflammatory mediator cytokine genes are closely linked and variably amplified on chromosome 17q. Nucleic Acids Res (1990) 1.30